Integra LifeSciences Holdings Corporation

Informe acción NasdaqGS:IART

Capitalización de mercado: US$2.2b

Integra LifeSciences Holdings Dirección

Dirección controles de criterios 4/4

El CEO de Integra LifeSciences Holdings' es Jan De Witte , nombrado en Dec 2021, tiene una permanencia de 2.33 años. compensación anual total es $6.39M, compuesta por 13.7% salario y 86.3% primas, incluidas acciones y opciones de la empresa. posee directamente un 0.023% de las acciones de la empresa, por valor de $521.43K. La antigüedad media del equipo directivo y de la junta directiva es de 3.8 años y 10.9 años, respectivamente.

Información clave

Jan De Witte

Chief Executive Officer (CEO)

US$6.4m

Compensación total

Porcentaje del salario del CEO13.7%
Permanencia del CEO2.3yrs
Participación del CEO0.02%
Permanencia media de la dirección3.8yrs
Promedio de permanencia en la Junta Directiva10.9yrs

Actualizaciones recientes de la dirección

Recent updates

Returns On Capital At Integra LifeSciences Holdings (NASDAQ:IART) Have Stalled

Feb 27
Returns On Capital At Integra LifeSciences Holdings (NASDAQ:IART) Have Stalled

We Think Integra LifeSciences Holdings (NASDAQ:IART) Can Stay On Top Of Its Debt

Feb 11
We Think Integra LifeSciences Holdings (NASDAQ:IART) Can Stay On Top Of Its Debt

Is Now An Opportune Moment To Examine Integra LifeSciences Holdings Corporation (NASDAQ:IART)?

Jan 14
Is Now An Opportune Moment To Examine Integra LifeSciences Holdings Corporation (NASDAQ:IART)?

Integra LifeSciences Holdings Corporation's (NASDAQ:IART) Price In Tune With Earnings

Dec 31
Integra LifeSciences Holdings Corporation's (NASDAQ:IART) Price In Tune With Earnings

Is Integra LifeSciences Holdings Corporation (NASDAQ:IART) Trading At A 46% Discount?

Dec 03
Is Integra LifeSciences Holdings Corporation (NASDAQ:IART) Trading At A 46% Discount?

Does Integra LifeSciences Holdings (NASDAQ:IART) Have A Healthy Balance Sheet?

Nov 06
Does Integra LifeSciences Holdings (NASDAQ:IART) Have A Healthy Balance Sheet?

Integra LifeSciences Holdings (NASDAQ:IART) Hasn't Managed To Accelerate Its Returns

Oct 24
Integra LifeSciences Holdings (NASDAQ:IART) Hasn't Managed To Accelerate Its Returns

Is Now An Opportune Moment To Examine Integra LifeSciences Holdings Corporation (NASDAQ:IART)?

Sep 22
Is Now An Opportune Moment To Examine Integra LifeSciences Holdings Corporation (NASDAQ:IART)?

Is Integra LifeSciences Holdings Corporation (NASDAQ:IART) Trading At A 38% Discount?

Aug 15
Is Integra LifeSciences Holdings Corporation (NASDAQ:IART) Trading At A 38% Discount?

Returns On Capital At Integra LifeSciences Holdings (NASDAQ:IART) Have Hit The Brakes

Jul 03
Returns On Capital At Integra LifeSciences Holdings (NASDAQ:IART) Have Hit The Brakes

Is There Now An Opportunity In Integra LifeSciences Holdings Corporation (NASDAQ:IART)?

Jun 19
Is There Now An Opportunity In Integra LifeSciences Holdings Corporation (NASDAQ:IART)?

Estimating The Fair Value Of Integra LifeSciences Holdings Corporation (NASDAQ:IART)

May 05
Estimating The Fair Value Of Integra LifeSciences Holdings Corporation (NASDAQ:IART)

These 4 Measures Indicate That Integra LifeSciences Holdings (NASDAQ:IART) Is Using Debt Reasonably Well

Apr 07
These 4 Measures Indicate That Integra LifeSciences Holdings (NASDAQ:IART) Is Using Debt Reasonably Well

Integra LifeSciences Holdings (NASDAQ:IART) Is Experiencing Growth In Returns On Capital

Mar 26
Integra LifeSciences Holdings (NASDAQ:IART) Is Experiencing Growth In Returns On Capital

At US$52.61, Is It Time To Put Integra LifeSciences Holdings Corporation (NASDAQ:IART) On Your Watch List?

Mar 14
At US$52.61, Is It Time To Put Integra LifeSciences Holdings Corporation (NASDAQ:IART) On Your Watch List?

Does Integra LifeSciences Holdings (NASDAQ:IART) Deserve A Spot On Your Watchlist?

Feb 27
Does Integra LifeSciences Holdings (NASDAQ:IART) Deserve A Spot On Your Watchlist?

Calculating The Fair Value Of Integra LifeSciences Holdings Corporation (NASDAQ:IART)

Feb 02
Calculating The Fair Value Of Integra LifeSciences Holdings Corporation (NASDAQ:IART)

We Think Integra LifeSciences Holdings (NASDAQ:IART) Can Stay On Top Of Its Debt

Jan 05
We Think Integra LifeSciences Holdings (NASDAQ:IART) Can Stay On Top Of Its Debt

Here's What To Make Of Integra LifeSciences Holdings' (NASDAQ:IART) Decelerating Rates Of Return

Dec 21
Here's What To Make Of Integra LifeSciences Holdings' (NASDAQ:IART) Decelerating Rates Of Return

When Should You Buy Integra LifeSciences Holdings Corporation (NASDAQ:IART)?

Dec 08
When Should You Buy Integra LifeSciences Holdings Corporation (NASDAQ:IART)?

Is Integra LifeSciences Holdings Corporation (NASDAQ:IART) Trading At A 42% Discount?

Oct 19
Is Integra LifeSciences Holdings Corporation (NASDAQ:IART) Trading At A 42% Discount?

We Think Integra LifeSciences Holdings (NASDAQ:IART) Can Stay On Top Of Its Debt

Oct 05
We Think Integra LifeSciences Holdings (NASDAQ:IART) Can Stay On Top Of Its Debt

Integra LifeSciences: Wide Dislocation In Fundamentals Vs. Market Value

Sep 13

Is It Time To Consider Buying Integra LifeSciences Holdings Corporation (NASDAQ:IART)?

Sep 06
Is It Time To Consider Buying Integra LifeSciences Holdings Corporation (NASDAQ:IART)?

FDA labels recall of intracranial pressure monitors by Integra as most serious

Aug 31

Integra Lifesciences voluntarily recalls pressure monitors, lowers revenue, profit guidance

Aug 24

Returns At Integra LifeSciences Holdings (NASDAQ:IART) Appear To Be Weighed Down

Aug 23
Returns At Integra LifeSciences Holdings (NASDAQ:IART) Appear To Be Weighed Down

Integra LifeSciences founder/former CEO dies

Aug 16

Integra LifeSciences Holdings GAAP EPS of $0.54 beats by $0.09, revenue of $398M beats by $2.62M

Jul 27

Is There An Opportunity With Integra LifeSciences Holdings Corporation's (NASDAQ:IART) 47% Undervaluation?

Jul 20
Is There An Opportunity With Integra LifeSciences Holdings Corporation's (NASDAQ:IART) 47% Undervaluation?

These 4 Measures Indicate That Integra LifeSciences Holdings (NASDAQ:IART) Is Using Debt Reasonably Well

Jul 07
These 4 Measures Indicate That Integra LifeSciences Holdings (NASDAQ:IART) Is Using Debt Reasonably Well

Análisis de compensación del CEO

¿Cómo ha cambiado la remuneración de Jan De Witte en comparación con los beneficios de Integra LifeSciences Holdings?
FechaCompensación totalSalarioIngresos de la empresa
Dec 31 2023US$6mUS$875k

US$68m

Sep 30 2023n/an/a

US$101m

Jun 30 2023n/an/a

US$131m

Mar 31 2023n/an/a

US$172m

Dec 31 2022US$9mUS$850k

US$181m

Sep 30 2022n/an/a

US$173m

Jun 30 2022n/an/a

US$166m

Mar 31 2022n/an/a

US$157m

Dec 31 2021US$899kUS$59k

US$169m

Compensación vs. Mercado: La compensación total ($USD6.39M) de Jan está en línea con el promedio de empresas de tamaño similar en el mercado US ($USD5.61M).

Compensación vs. Ingresos: La compensación de Jan ha sido consistente con los resultados de la empresa en el último año.


CEO

Jan De Witte (59 yo)

2.3yrs

Permanencia

US$6,388,756

Compensación

Mr. Jan De Witte has been President, Chief Executive Officer & Director of Integra LifeSciences Holdings Corporation since December 1, 2021. He had been the Chief Executive Officer at Barco NV since Septem...


Equipo directivo

NombrePosiciónPermanenciaCompensaciónPropiedad
Stuart Essig
Executive Chairman26.3yrsUS$422.52k2.15%
$ 47.8m
Jan De Witte
President2.3yrsUS$6.39m0.023%
$ 520.1k
Lea Knight
Executive VP & CFOless than a yearUS$1.67m0.057%
$ 1.3m
Jeffrey Mosebrook
Senior VP of Finance & Principal Accounting Officer6.5yrsUS$1.25m0.034%
$ 762.9k
Eric Schwartz
Executive VP5.4yrsUS$1.62m0.081%
$ 1.8m
Robert Davis
Executive VP & President of Tissue Technologies11.3yrsUS$1.42m0.083%
$ 1.8m
Michael McBreen
Executive VP & President of Codman Specialty Surgical3.9yrsUS$2.83m0.074%
$ 1.6m
Stephen Leonard
Corporate VP of Global Operations & Supply Chain3.7yrssin datossin datos
Mathieu Aussermeier
Vice President of Corporate Financeno datasin datossin datos
William Compton
Chief Information Officer & Corporate VPno datasin datossin datos
Laurene Isip
Vice President of Global Corporate Communications & Public Relationsno datasin datossin datos
Ruth Fleming
Vice President of Global Marketingno datasin datossin datos

3.8yrs

Permanencia media

57.5yo

Promedio de edad

Equipo directivo experimentado: El equipo directivo de IART se considera experimentado (3.8 años antigüedad media).


Miembros de la Junta

NombrePosiciónPermanenciaCompensaciónPropiedad
Stuart Essig
Executive Chairman26.3yrsUS$422.52k2.15%
$ 47.8m
Jan De Witte
President2.3yrsUS$6.39m0.023%
$ 520.1k
Raymond Murphy
Independent Director15yrsUS$297.54k0.094%
$ 2.1m
Christian Schade
Independent Director18.3yrsUS$313.80k0.070%
$ 1.6m
Barbara Hill
Independent Presiding Director10.9yrsUS$342.54k0.11%
$ 2.5m
Keith N. Bradley
Independent Director32.3yrsUS$306.31k0.078%
$ 1.7m
Jeffrey Graves
Independent Directorless than a yearUS$90.68k0.0028%
$ 62.8k
Shaundra Clay
Independent Director3yrsUS$280.05k0.017%
$ 374.9k
Renee Lo
Independent Director1.8yrsUS$191.78k0.0095%
$ 211.2k

10.9yrs

Permanencia media

62yo

Promedio de edad

Junta con experiencia: Los miembros de la junta directiva de IART son experimentados ( 10.9 años antigüedad media).